The algorithm includes immunohistochemical evaluation of MMR proteins and p53 expression in all cases of endometrial carcinoma, whereas POLE sequencing is to be restricted to early-stage cases with at least one of the following histopathologic features: (i) non-endometrioid histotypes (i.e., dedifferentiated/undifferentiated carcinoma), (ii) high-grade, (iii) substantial LVSI, (iv) stage IB-II. The gene discussed is TP53; the disease is undifferentiated carcinoma.